Although GenomiCare did not disclose the size of the A round, the company did say it has raised $25M since its inception in 2015.
December 1, 2017 -- GenomiCare Biotechnology, a Shanghai precision medicine company for cancer, completed a Series A financing co-launched by Morningside Venture Capital, Apricot Tree Capital and Carebridge Holdings. Although GenomiCare did not disclose the size of the A round, the company did say it has raised $25 million since its inception in 2015. The company stresses early diagnosis plus precision, full-solution therapy. China Renaissance Group provides financial consulting services for GenomiCare.
